Abivax (ABVX) Cash & Equivalents (2021 - 2026)

Abivax's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $558.9 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 413.03% year-over-year to $558.9 million in Q1 2026; TTM through Mar 2026 was $558.9 million, a 413.03% increase from a year earlier, with the FY2025 full-year figure at $601.4 million, up 285.36% from the prior year.
• Cash & Equivalents retreated to $558.9 million in Q1 2026 per ABVX's latest filing, from $601.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $689.4 million in Q3 2025 and bottomed at $27.5 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $239.4 million (2024), against an average of $302.2 million.
• Across the five-year window, Cash & Equivalents jumped 885.88% in 2023 and plunged 71.18% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $27.5 million in 2022, then jumped by 885.88% to $271.1 million in 2023, then sank by 43.16% to $154.1 million in 2024, then soared by 290.32% to $601.4 million in 2025, then dropped by 7.07% to $558.9 million in 2026.
• Per Business Quant, the three latest ABVX Cash & Equivalents figures stand at $558.9 million (Q1 2026), $601.4 million (Q4 2025), and $689.4 million (Q3 2025).